目的：对优化均匀设计的气血并治方有效组分D、E、F进行不同配伍配比的进一步验证，观察和比较其对高脂血症模型大鼠的病理环节作用强度和作用靶点的差异。方法：采用SD大鼠，100只，其中90只给予高脂饲料喂食7天后，随机分层分组：全方组；D、E原方配伍组；D、E优化配伍组；D、E优全之间组；D、E优化反伍组；原方配伍加F组；优化配伍加F组；气血并治方组分D主要为芍药苷约占49.12%、E组分主要为总黄酮约占30.0%，F组分主要为总酸约占32.07%；阳性药物对照组（血脂康，0.108 g?kg-1）和高脂模型组。另设空白对照组（喂普通饲料）。各药物组按药物配伍比例给予灌胃14天后，动物麻醉后取血测定血脂、血小板聚集性、血管活性物质和炎症水平指标。结果：与模型组比较，气血并治方有效组分D、E原方配伍组及优化配伍组对胆固醇（TC）有显著降低作用（P<0.05），优化配伍组降低TC的水平最低为（3.49±0.86）mmol?L-1；全方组、D、E原方配伍组和优化配伍组对血小板最大聚集率有显著抑制作用（P<0.05，P<0.01），而优化反配伍（D、E反比例）组则无作用；D、E原方配伍组、优化配伍组及优全之间组对6-酮-前列腺素F1α（6-Keto-GPF1α）有显著升高作用（P<0.05），D、E优化组对内皮素（ET）有降低作用（P<0.05），其他各组对血管活性物质没有显著影响；全方组、D、E原方配伍加F组对白介素-6（IL-6）、白介素-8（IL-8）水平有显著抑制作用（P<0.05，P<0.01）。结论：气血并治方有效组分原方配伍和优化配伍的作用环节及作用强度有一定差异，加入F部位后对炎症水平的抑制作用有一定的增强。

This study was aimed to optimize the uniform design for effective constituents in water-soluble extractives D, E, F of traditional Chinese medicine(TCM) in Qi-Xue Bing-Zhi Fang(QXBZF) for the further validation of the ratio of different compatibility. A total of 100 SD rats were used in the study. Among them, 90 rats were given high fat feeding for 7 days. Then, stratified randomization was used. The rats were divided into the all-party group; D, E original prescription group; D, E optimized compatible group; D, E between optimized and original group; D, E optimized but anti-compatibility group; all-party group adding F; optimized compatible group adding F; QXBZF with mainly paeoniflorin accounted for 49.12% as component D, total flavonoids accounted for 30.0% as component E, total acids accounted for 32.07% in component F; the positive drug control group (Xue-Zhi-Kang, 0.108 g/kg); and the high fat model group. In addition, a blank control group (with normal diet) was set. Each group was treated with gastric perfusion according to drug compatibility proportion for 14 days. Rats were sacrificed to take blood samples for the detection of serum lipid, platelet aggregation, vasoactive substance, and inflammation level. The results showed that compared with the model group, the QXBZF D, E original prescription group and D, E optimized compatible group had significant decreasing effects on TC (P < 0.05). The lowest level of TC decreased by optimized compatible group was(3.49 ± 0.86) mmol/L. The all-party group, D, E original prescription group and optimized compatible group can inhibit the platelet with maximum aggregation rate effectively(P < 0.05, P < 0.01); while the D, E optimized but anti-compatibility group (with D, E inverse proportion) had no effect on it. All-party group and the D, E original group adding F had significant inhibition on IL-6 and IL-8(P < 0.05, P < 0.01). The D, E original prescription group, D, E optimized compatible group and D, E between optimized and original group can ascend 6-Keto-PGF1α significantly(P < 0.05). ET-1 was decreased in the D, E optimized compatible group(P < 0.05). Other groups had no obvious effect on vascular active substances. It was concluded that different effects between the QXBZF D, E original prescription group and the D, E optimized compatible group were observed in action segment and strength. When F parts added, inhibitions of inflammation levels were enhanced at certain level.

科学技术部国家重点基础研究发展规划项目“973”计划（G19990544-05）：方剂关键科学问题的基础研究——气血并治复方防治动脉粥样硬化（AS）的研究，主课题负责人：王永炎，张伯礼，子课题负责人：史大卓，程翼宇；国家自然科学基金委面上项目（81273933）：益气活血中药配伍与双抗血小板药物相互作用的机理研究，负责人：史大卓。